25,000 Shares in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. acquired a new stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,000 shares of the company’s stock, valued at approximately $32,000. Vontobel Holding Ltd. owned about 0.08% of Actinium Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in shares of Actinium Pharmaceuticals in the 3rd quarter valued at $322,000. XTX Topco Ltd acquired a new position in shares of Actinium Pharmaceuticals in the third quarter valued at approximately $268,000. Wellington Management Group LLP bought a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at $112,000. Creative Financial Designs Inc. ADV raised its stake in shares of Actinium Pharmaceuticals by 183.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock valued at $120,000 after purchasing an additional 41,250 shares during the period. Finally, Barclays PLC boosted its position in shares of Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after buying an additional 32,784 shares during the period. Institutional investors and hedge funds own 27.50% of the company’s stock.

Analyst Ratings Changes

ATNM has been the subject of a number of analyst reports. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Price Performance

Shares of NYSE ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a PE ratio of -0.84 and a beta of 0.13. Actinium Pharmaceuticals, Inc. has a fifty-two week low of $1.07 and a fifty-two week high of $10.24. The business has a fifty day moving average price of $1.24 and a two-hundred day moving average price of $1.57.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).